March 18, 2009 – Bioptics Inc., which develops imaging technology for the detection and treatment of cancer, announced at the NCBC 2009 annual conference that the FDA has granted it 510(k) clearance to use the Core VISION, a specimen radiography system, to analyze Core Biopsy samples.
The Core VISION is small, simple to operate and has been ergonomically designed to speed the workflow during biopsy procedures and the results can be readily viewed by various clinicians through their standard PACS network and offers the highest resolution of any product in its class. The Core VISION is radiation shielded, interlocked and can be readily deployed in stereotactic procedure rooms.
“The Core VISION complements our range of specimen radiography products and greatly enhances workflow during core biopsy procedures at a very cost effective price,” said Market Development Manager Cheryl Augello.
For more information: www.bioptics-inc.com
October 30, 2026 
